<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05034978</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol HK POCT study</org_study_id>
    <nct_id>NCT05034978</nct_id>
  </id_info>
  <brief_title>Novel SARS-CoV-2 Point-of-care Testing</brief_title>
  <official_title>Point-of-care Testing for Improving the Detection of SARS-CoV-2 Infection in Healthcare Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the project is to study the feasibility of implementing a novel point-of-care test&#xD;
      (POCT) for rapid detection of SARS-CoV-2 infection. A CRISPR-based detection kit would be&#xD;
      piloted for testing of suspected SARS-CoV-2 infection in healthcare setting, with the&#xD;
      objectives of evaluating the performance of the new test in the detection of SARS-CoV-2, and&#xD;
      assessing the practicability of the new test for diagnosing SARS-CoV-2 infection in&#xD;
      healthcare settings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A CRISPR-based lateral flow assay (LFA) detection kit would be designed and developed for&#xD;
      testing for the presence of SARS-CoV-2. The aim of the project is to study the feasibility of&#xD;
      implementing the novel point-of-care test (POCT) for rapid detection of SARS-CoV-2 infection&#xD;
      in health service setting, with the following objectives: (b) Evaluation of the performance&#xD;
      of novel POCT in comparison with conventional quantitative PCR in diagnosis SARS-CoV-2&#xD;
      infection and (c) Assessment of the practicability of LFA-CRISPR-based tests in the operating&#xD;
      environments in healthcare settings.&#xD;
&#xD;
      Patients who are admitted to the isolation wards of Prince of Wales Hospital, Hong Kong would&#xD;
      be invited to join the study. A total of 600 persons with suspected SARS-CoV-2 infection&#xD;
      presenting with different symptomatology and epidemiological history will be recruited.&#xD;
      Nasal, deep saliva and/or mouth gargle samples will be collected from all recruited subjects&#xD;
      in accordance with standard clinical protocol. The samples would be tested for SARS-CoV-2 by&#xD;
      the new Point-of-care test, in parallel with standard diagnostic testing of the hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2021</start_date>
  <completion_date type="Anticipated">September 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 15, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Test performance</measure>
    <time_frame>1 year</time_frame>
    <description>agreement of point-of-care test result and conventional test</description>
  </primary_outcome>
  <enrollment type="Anticipated">600</enrollment>
  <condition>SARS-CoV2 Infection</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <description>evaluating the performance of a novel point-of-care test</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        persons with exposure risk to SARS-CoV-2 infection who subsequently test positive or&#xD;
        negative to conventional PCR-based testing for the diagnosis of the infection.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patients admitted to isolation wards of the hospital who are&#xD;
&#xD;
          -  of age of 18 or above;&#xD;
&#xD;
          -  presentation with symptoms of COVID-19 and/or&#xD;
&#xD;
          -  demonstration of exposure risk to SARS-CoV-2 infection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  inability to communicate in English or Chinese;&#xD;
&#xD;
          -  known history of mental illness;&#xD;
&#xD;
          -  prisoners.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Shui Shan Lee, MD</last_name>
    <phone>85261703177</phone>
    <email>sslee@cuhk.edu.hk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Stanley Ho Centre for Emerging Infectious Diseases, The Chinese University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <zip>0000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shui Shan S Lee, MD</last_name>
      <phone>85261703177</phone>
      <email>sslee@cuhk.edu.hk</email>
    </contact>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Shui-Shan Lee, MD</investigator_full_name>
    <investigator_title>Research Professor</investigator_title>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>point-of-care testing</keyword>
  <keyword>rapid diagnostics</keyword>
  <keyword>Hong Kong</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participants data are not collected</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

